⌂
Home
◈
Markets
▦
Screener
📈
Tools
◎
Portfolio
Skip to content
DFM General
5,851.39
−0.27%
FTSE ADX
9,783.24
−0.26%
TASI
10,123.62
−0.65%
QE Index
8,632.66
−0.01%
S&P 500
7,690.73
+0.41%
Nasdaq 100
29,529.34
+1.17%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
166,161.66
+0.12%
DFM:EMIRATESNBD
AED 31.50
−0.25%
ADX:IHC
AED 352.00
−0.17%
SAU:2222
SAR 25.80
+0.00%
DSMD:QNBK
QAR 15.66
+2.29%
NAS:NVDA
$217.09
+1.38%
NYSE:TSM
$420.22
+1.84%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 300.11
+0.21%
Gold
$4,135.86
−0.12%
Brent
$109.93
+0.65%
BTC
$81,886.30
+0.05%
ETH
$2,404.89
−0.01%
DFM General
5,851.39
−0.27%
FTSE ADX
9,783.24
−0.26%
TASI
10,123.62
−0.65%
QE Index
8,632.66
−0.01%
S&P 500
7,690.73
+0.41%
Nasdaq 100
29,529.34
+1.17%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
166,161.66
+0.12%
DFM:EMIRATESNBD
AED 31.50
−0.25%
ADX:IHC
AED 352.00
−0.17%
SAU:2222
SAR 25.80
+0.00%
DSMD:QNBK
QAR 15.66
+2.29%
NAS:NVDA
$217.09
+1.38%
NYSE:TSM
$420.22
+1.84%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 300.11
+0.21%
Gold
$4,135.86
−0.12%
Brent
$109.93
+0.65%
BTC
$81,886.30
+0.05%
ETH
$2,404.89
−0.01%
☰
Markets
▼
Stock markets
🇦🇪
UAE
DFM · ADX · DFM General
Closed
🇸🇦
Saudi Arabia
Tadawul · TASI
Closed
🇶🇦
Qatar
QSE · QE General
Closed
🇺🇸
United States
Nasdaq · NYSE · S&P 500
Closed
🇮🇳
India
NSE · BSE · Nifty 50
Closed
🇵🇰
Pakistan
PSX · KSE-100
Open
Other assets
₿
Crypto
Ranked by volume · 24/7
🥇
Gold, FX & economy
Dubai gold, AED crosses, rates
◫
ETFs
Index, sector and gold funds
Explore
▦
Market map
Every market as a heatmap
📅
Calendar & IPOs
Earnings, dividends, listings, releases
⌁
Options flow · Ownership · Politics
US filings and tapes
Screener
▼
⚲
Stock screener
All six markets, one row per company
★
Ready-made screens
Starting points with a point of view
📁
My saved screens
Saved rules with alerts on new matches
⇄
Compare
Up to five, side by side
Crypto
Tools
▼
📈
Charting
Drawings, indicators, replay
▶
Strategy Maker
Write a rule, test it on history
⇄
Compare
Side by side
🔔
Alerts
Price, earnings, screens, strategies
News
Portfolio
⌕
AED
USD
SAR
QAR
INR
PKR
GBP
EUR
KWD
OMR
BHD
☆
♢
☾
Sign in
Create account
👤
Markets
› LSE
› AZN.L
A
AstraZeneca PLC
LSE:AZN.L
Healthcare
FTSE:ASX
FTSE:NMX
£124.00
−0.37%
At close
At close · Mon 19 Oct · ≈
AED 606.94
· Market cap
$257.26B
· Next earnings
Fri 30 Oct
☆
Watch
🔔
Alert
⇄
Compare
▶
Test a strategy
✦
AI read
Overview
Chart
Financials
Valuation
Forecasts
Dividends
News
Profile
AstraZeneca PLC · News · TradingHolo
AZN.L news
Headlines tagged to this company
ST
Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts
Stocktwits · 3 d ago
SH
Weekly review
ShareCast · 4 d ago
DO
AstraZeneca's New Rare-Disease Drug Can Overcome Regulatory Risk — Market Talk
Dow Jones Newswires · 4 d ago
RE
China biotech's ingenuity extends to dealmaking
Reuters · 4 d ago
RE
Weight-loss drug developers line up to tap lucrative market as competition heats up
Reuters · 4 d ago
RE
EMA's CHMP Recommends Extension Of Therapeutic Indication For Pandemic Influenza Vaccine H5N1 AstraZeneca
Reuters · 4 d ago
SH
AstraZeneca enters into strategic drug discovery deal with AI biotech Insitro
ShareCast · 5 d ago
DO
AstraZeneca Strikes Up to $1.5 Billion AI Drug Discovery Deal With Insitro
Dow Jones Newswires · 5 d ago
ST
AstraZeneca, insitro Strike AI Drug Discovery – What Investors Need To Know
Stocktwits · 5 d ago
SE
AstraZeneca inks AI drug discovery deal worth up to $1.5B with insitro
Seeking Alpha · 5 d ago
RE
AstraZeneca Secures Exclusive Global Rights to Selected Programs Under Insitro Collaboration
Reuters · 5 d ago
RE
Insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies
Reuters · 5 d ago
RE
AstraZeneca strikes $40 million AI drug discovery deal with insitro
Reuters · 5 d ago
RE
Pharma sector doubles down on AI to slash costs, timelines
Reuters · 6 d ago
RE
These names could surprise - to the upside or downside - Jefferies says
Reuters · 7 d ago
DO
AstraZeneca's Latest Data on Rare-Disease Drug Supports Sales Potential — Market Talk
Dow Jones Newswires · 8 d ago
RE
Astrazeneca Says Efzimfotase Alfa Shows Improvement In Primary And Key Secondary Endpoints At Week 25 And Week 49
Reuters · 8 d ago
DO
AstraZeneca Executive Sees Path for Bone-Disease Drug Approval Despite Trial Miss — Interview
Dow Jones Newswires · 8 d ago
SE
Hospital group files lawsuit to stop 340B rebate pilot again
Seeking Alpha · 10 d ago
More news →